|Study Description:||The purpose of this study is to compare the effects, good and/or bad of three |
drug combinations. The first combination is the standard treatment of
daunorubicin plus AraC. This is called “7+3” treatment. The second
combination is another standard treatment of idarubicin plus AraC. This is
called “IA” treatment. Both of these treatments have been approved for your
cancer. The third combination will add the drug vorinostat to the standard IA
therapy. Vorinostat is approved for other types of cancer, but has not been
approved for your type of cancer, so it is considered investigational for this
study. We want to compare the effects of these three treatments on your type
We want to see if the study treatments will get rid of leukemia cells and keep
them from coming back for patients who may benefit from stem cell transplant.
We also want to see if we can find stem cell transplant donors for patients who
might benefit from a transplant according to standard practice, beginning at
the time you register for the study.